LionBio

LionBio

LionBio is developing nanoparticle-based GLP-1 treatments delivered through the nose, with its first candidate being a nasal formulation of semaglutide. The startup aims to expand into peptide treatments for neurological conditions and targets the olfactory epithelium for drug delivery to the brain. This pre-seed round will support its preclinical development and manufacturing scale-up.

Total raised
Undisclosed
tracked to date
Latest round
Pre-seed
Nov 6, 2026
Known investors
1
led by South Park Commons

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q4 2026 USA Funding Report

Read the Q4 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q4-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q4 2026 USA Funding Report</a>

Funding history

  1. 1
    $6 million pre-seedPre-seedNov 6, 2026

    Led by South Park Commons

    Announcement ↗

Founder

Robin Guo
Robin Guo
Chief executive officer

Investors in LionBio

Backers from this company's tracked funding rounds.

  • SSouth Park CommonsLead investorVC firm

LionBio in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile